56.3 Chronic Electrolyte & Acid-Base Management in CKD

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

56.3 Chronic Electrolyte & Acid-Base Management in CKD

Key Takeaways Explain This Topic AI

Chronic metabolic acidosis in CKD results from defective renal ammoniagenesis and impaired bicarbonate reabsorption; maintaining serum bicarbonate >=22 mEq/L (target 22-26 mEq/L) with oral sodium bicarbonate (650 mg BID-TID; 1 tablet = 7.7 mEq HCO3-) prevents accelerated skeletal muscle proteolysis, preserves bone mineral density, and slows CKD progression.

CKD-Mineral and Bone Disorder (CKD-MBD) is initiated by phosphate retention triggering osteocytic FGF-23 release, which downregulates renal 1-alpha-hydroxylase, reducing calcitriol (1,25-OH2D3) and resulting in hypocalcemia; the triad of hyperphosphatemia, hypocalcemia, and calcitriol deficiency produces severe secondary hyperparathyroidism and renal osteodystrophy.

CKD-MBD pharmacotherapy: phosphate binders (dietary restriction 800-1000 mg/day; calcium acetate limited to <1500 mg/day elemental calcium to avoid vascular calcification; sevelamer or lanthanum if hypercalcemic) control phosphorus; secondary hyperparathyroidism is treated with active vitamin D analogues (calcitriol, paricalcitol) or calcimimetics (cinacalcet, which activates CaSR to suppress PTH without raising calcium or phosphate).

Novel non-absorbed oral potassium binders—patiromer (calcium-exchanger in colon, 3-hour separation rule) and sodium zirconium cyclosilicate (SZC/Lokelma, rapid onset 1-2 hours)—permit the safe maintenance and uptitration of cardioprotective and renoprotective RAAS inhibitors in patients with recurrent hyperkalemia.

Anemia of CKD is predominantly normocytic and normochromic, caused by inadequate renal erythropoietin production; prior to initiating Erythropoiesis-Stimulating Agents (ESAs), iron deficiency must be corrected (target TSAT >20-30%, ferritin >100-500 ng/mL); ESAs are initiated when Hb <10 g/dL with a strict Black Box Warning target not exceeding 11.5 g/dL to avoid excess stroke, venous thromboembolism, and cardiovascular death.

Last updated: September 2026

Chronic Metabolic Acidosis in CKD: Pathophysiology & Oral Alkali Therapy

Metabolic acidosis is an almost universal complication of progressive chronic kidney disease, typically emerging when the estimated GFR drops below 30 to 45 mL/min/1.73 m² (Stages G3b through G5).

Renal Acid-Base Physiology & Pathogenesis

Under normal physiological conditions, the human diet generates approximately 1 mEq/kg/day of non-volatile (fixed) acids (primarily sulfuric acid derived from the catabolism of sulfur-containing amino acids: methionine and cysteine). To maintain systemic acid-base equilibrium, the kidneys must perform two functions:

Reabsorb all filtered bicarbonate (~4,500 mEq/day), primarily in the proximal convoluted tubule.

Excrete the daily net fixed acid load through renal ammoniagenesis (proximal tubular conversion of glutamine into ammonium [ N H 4 + NH_4^+ N H 4 + ] and alpha-ketoglutarate) and titratable acid excretion (primarily monobasic phosphate, H 2 P O 4 − H_2PO_4^- H 2 P O 4 − ).

In chronic kidney disease, as functional nephron mass is destroyed:

Early CKD (eGFR 30 to 60 mL/min) : Total renal ammonium synthesis declines. The remaining intact nephrons maximally upregulate ammoniagenesis per nephron, but overall net acid excretion falls short. Retention of hydrogen ions with compensatory chloride retention produces a Normal Anion Gap (Hyperchloremic) Metabolic Acidosis .

Advanced CKD (eGFR < 30 mL/min, Stages G4-G5) : Renal excretion of unmeasured fixed organic and inorganic anions (sulfate, phosphate, urate, hippurate) fails. These retained anions accumulate in the circulation, converting the acid-base disorder into a High Anion Gap Metabolic Acidosis .

Adverse Systemic Sequelae of Chronic Acidosis

Chronic untreated metabolic acidosis is not merely a laboratory abnormality; it is an active driver of multi-organ decline:

Accelerated Skeletal Muscle Proteolysis & Sarcopenia : Acidemia upregulates the ATP-dependent ubiquitin-proteasome proteolytic pathway and stimulates caspase-3 in skeletal myocytes. This drives rapid breakdown of myofibrillar proteins, inducing severe sarcopenia, frailty, and protein-energy wasting (PEW).

Bone Demineralization & Osteopenia : Extracellular hydrogen ions are buffered directly by the skeleton. Protons stimulate osteoclasts and physicochemical dissolution of bone mineral ( calcium hydroxyapatite , C a 10 ( P O 4 ) 6 ( O H ) 2 Ca_{10}(PO_4)_6(OH)_2 C a 10 ( P O 4 ) 6 ( O H ) 2 ), releasing carbonate, calcium, and phosphate into the circulation, worsening metabolic bone disease and arterial calcification.

Accelerated CKD Progression : Intrarenal acidosis stimulates the local production of endothelin-1, angiotensin II, aldosterone, and the alternative complement pathway within renal tubules, generating chronic tubulointerstitial inflammation, capillary rarefaction, and progressive nephron fibrosis.

Endocrine Dysregulation : Induces peripheral insulin resistance, impairs thyroid hormone metabolism, and suppresses growth hormone/IGF-1 signaling.

Treatment Targets & Oral Alkali Pharmacotherapy KDIGO RECOMMENDATIONS FOR METABOLIC ACIDOSIS

Parameter Clinical Guideline Recommendation
═════════════════════════════════════════════════════════════════════════════════════════════
Serum Bicarbonate Goal Maintain serum bicarbonate >= 22 mEq/L (Target Range: 22 to 26 mEq/L)
Do NOT exceed 26 to 28 mEq/L (avoids metabolic alkalosis & calcification)

First-Line Therapy Oral Sodium Bicarbonate (NaHCO3) 650 mg tablets
1 tablet (650 mg) provides 7.7 mEq of bicarbonate and 7.7 mEq of sodium
Starting Dose: 650 mg PO BID to TID (15 to 23 mEq/day)
Titrate every 2-4 weeks until serum HCO3- is >= 22 mEq/L

Alternative Therapy Oral Sodium Citrate (Bicitra / Shohl solution)
1 mL provides 1 mEq sodium and 1 mEq bicarbonate equivalent

Contraindication: NEVER co-administer with aluminum antacids!

(Citrate increases aluminum absorption tenfold, causing encephalopathy)

Monitoring Priorities Monitor office blood pressure, peripheral edema, and weight.

(Sodium bicarbonate causes significantly less volume expansion than NaCl)
═════════════════════════════════════════════════════════════════════════════════════════════

CKD-Mineral and Bone Disorder (CKD-MBD) & Secondary Hyperparathyroidism

CKD-Mineral and Bone Disorder (CKD-MBD) is a complex systemic syndrome that develops in virtually all patients with advanced CKD. It is defined clinically by a triad of interrelated pathology:

Biochemical abnormalities : Derangements in serum calcium, phosphorus, Parathyroid Hormone (PTH), Fibroblast Growth Factor 23 (FGF-23), and active vitamin D ( 1 , 25 ( O H ) 2 D 3 1,25(OH)_2D_3 1 , 25 ( O H ) 2 D 3 ).

Bone histomorphometry abnormalities (Renal Osteodystrophy) : High-turnover bone disease (osteitis fibrosa cystica) vs. low-turnover bone disease (adynamic bone disease and osteomalacia).

Vascular and soft-tissue calcification : Medial arterial calcification ( Mönckeberg sclerosis ), coronary and peripheral artery calcification, cardiac valvular stenosis, and fatal calciphylaxis (calcific uremic arteriolopathy). THE PATHOPHYSIOLOGIC CASCADE OF CKD-MBD

Progressive Loss of Nephron Mass (eGFR drops < 60 mL/min/1.73 m²)
│
▼
Impaired Renal Phosphate Filtration ──► Subtle Phosphate Retention
│
▼
Osteocytes Secrete Fibroblast Growth Factor 23 (FGF-23) [via Klotho co-receptor]
(Compensatory phosphaturia keeps serum phosphorus normal early on)
│
▼
FGF-23 & Decreased Renal Mass Downregulate Renal 1-alpha-Hydroxylase (CYP27B1)
(Inhibition of calcidiol conversion to active 1,25-dihydroxyvitamin D)
│
▼
Severe Deficiency of Active Calcitriol [1,25(OH)2D3]
│
▼
Impaired Intestinal Calcium Absorption ──► Hypocalcemia
│
┌────────────────────────────────┴────────────────────────────────┐
▼ ▼
Loss of Calcitriol-Mediated Hypocalcemia (decreased CaSR) Hyperphosphatemia
Negative Feedback on Parathyroid stimulates PTH transcription stimulates PTH synthesis
Gland pre-pro-PTH gene and chief cell proliferation directly
└────────────────────────────────┬────────────────────────────────┘
│
▼
SECONDARY HYPERPARATHYROIDISM (SHPT)
(Massive parathyroid gland hyperplasia, osteoclast activation, renal osteodystrophy,
subperiosteal bone resorption [rugger-jersey spine], vascular calcification)
Evidence-Based Treatment Strategies for CKD-MBD PHARMACOTHERAPY SPECTRUM FOR CKD-MBD

Drug Class & Agent Mechanism of Action Clinical Pearls & Safety Warnings
═════════════════════════════════════════════════════════════════════════════════════════════════════

Dietary Phosphate Limits gastrointestinal Daily target: 800 to 1,000 mg/day.

Restriction phosphate load ELIMINATE processed food additives
(fast foods, dark colas, processed meats;
inorganic phosphate is 100% absorbed!)

Calcium-Based Binders Binds dietary phosphate in gut First-line, inexpensive.

Calcium Acetate (PhosLo) lumen to form insoluble MANDATORY RULE: Limit total elemental
Calcium Carbonate (TUMS) calcium phosphate, excreted calcium from binders to < 1,500 mg/day
in feces. Must take WITH MEALS! (total intake < 2,000 mg) to prevent

severe arterial & valvular calcification!

Non-Calcium Binders Binds dietary phosphate in gut PREFERRED when serum calcium is elevated
Sevelamer Carbonate lumen WITHOUT absorbing calcium (> 9.5-10.0 mg/dL), PTH is low, or severe

(Renvela 800 mg TID) or metals. Must take WITH MEALS! vascular calcification is documented.

• Lanthanum Carbonate Sevelamer also binds bile acids, lowering

(Fosrenol 500-1000 mg) LDL-cholesterol by 15% to 30%.

Active Vitamin D Sterols Directly binds VDR in parathyroid Potently suppresses PTH transcription.

• Calcitriol (oral/IV) chief cells to downregulate HIGH RISK of inducing hypercalcemia and

• Paricalcitol (selective) pre-pro-PTH gene transcription hyperphosphatemia by stimulating GI absorption.

Hold if Ca > 10.2 mg/dL or P > 5.5 mg/dL.

Calcimimetics Allosterically activates the Suppresses PTH WITHOUT increasing calcium

Cinacalcet (Sensipar Calcium-Sensing Receptor (CaSR) or phosphorus (in fact, it LOWERS calcium!).

30 to 90 mg daily) on parathyroid chief cells, Risk of symptomatic hypocalcemia;

Etelcalcetide (IV on HD) increasing sensitivity to calcium monitor serum calcium within 1 week of start.

═════════════════════════════════════════════════════════════════════════════════════════════════════

Chronic Hyperkalemia Management & Novel Intestinal Potassium Binders

Hyperkalemia is a life-threatening electrolyte derangement defined by a serum potassium > 5.0 mEq/L (severe if > 6.0 to 6.5 mEq/L), occurring with high frequency in patients with CKD Stages G3b through G5.

Pathophysiology of Hyperkalemia in CKD

Renal potassium elimination occurs almost exclusively in the cortical collecting duct (CCD) via principal cells:

Basolateral N a + / K + Na^+/K^+ N a + / K + -ATPase pumps sodium out and potassium in.

Luminal epithelial sodium channels ( ENaC ) reabsorb sodium, creating a lumen-negative transepithelial potential difference.

This electrical gradient drives potassium secretion into the tubular lumen through ROMK (renal outer medullary potassium) channels and BK (big potassium / maxi-K) channels, stimulated by aldosterone and distal nephron sodium delivery.

In CKD, hyperkalemia develops from a confluence of factors: reduced total functioning nephron mass, impaired distal flow, tubular aldosterone unresponsiveness, metabolic acidosis (which shifts intracellular potassium into the extracellular compartment via H + / K + H^+/K^+ H + / K + exchange), and essential medications that block the renin-angiotensin-aldosterone axis (ACE inhibitors, ARBs, MRAs, beta-blockers, trimethoprim, NSAIDs).

The Modern Clinical Paradigm: Preserving Renoprotective Therapy

The Historic Clinical Pitfall : Previously, when serum potassium reached 5.2 to 5.5 mEq/L, clinicians routinely discontinued ACE inhibitors, ARBs, and MRAs. Discontinuing these agents directly accelerates CKD progression and increases cardiovascular mortality.

The Modern Guideline Approach : Current KDIGO 2024 guidelines strongly recommend maintaining and optimizing vital RAAS inhibitor therapy by utilizing dietary counseling and novel non-absorbed gastrointestinal potassium binders to manage serum potassium. NOVEL NON-ABSORBED POTASSIUM BINDERS

Feature Patiromer (Veltassa) Sodium Zirconium Cyclosilicate (SZC / Lokelma)
══════════════════════════════════════════════════════════════════════════════════════════════════════════
Chemical Nature Non-absorbed cross-linked polymer bead Insoluble inorganic crystalline zirconium silicate

Counter-Ion Calcium-sorbitol complex Sodium and hydrogen cations

Primary Site Distal colon Entire GI tract (stomach, small intestine, colon)
of Action (where luminal K+ concentration is highest) (Highly selective 3-Angstrom crystal micropores)

Onset of Action 4 to 7 hours 1 to 2 hours
(Slow onset; maintenance therapy) (Rapid onset; useful for urgent correction)

Dosing Regimen 8.4 g powder packet PO once daily Correction: 10 g PO TID with water for up to 48 hours
with food; titrate up to 25.2 g daily Maintenance: 5 to 10 g PO once daily

Critical Drug SEPARATE BY AT LEAST 3 HOURS SEPARATE BY AT LEAST 2 HOURS
Interaction Rule from all other oral medications! from drugs with pH-dependent gastric absorption
(Binds and reduces drug bioavailability) (e.g., azoles, protease inhibitors, levothyroxine)

Adverse Effects Constipation, diarrhea, flatulence; Peripheral edema and sodium retention
Hypomagnesemia (binds Mg2+ in colon) (Each 5 g dose contains ~400 mg elemental sodium)
══════════════════════════════════════════════════════════════════════════════════════════════════════════

Anemia of Chronic Kidney Disease: Diagnostic Evaluation & ESA Protocol

Anemia is a characteristic complication of chronic kidney disease, typically manifesting when eGFR falls below 45 mL/min/1.73 m² and present in over 90% of patients with Stage G5 CKD. It contributes substantially to fatigue, cognitive impairment, left ventricular hypertrophy (LVH), heart failure decompensation, and cardiovascular mortality.

Multifactorial Pathophysiology of CKD Anemia

Primary Driver: Deficiency of Erythropoietin (EPO) :

In healthy adults, >90% of erythropoietin is synthesized by specialized peritubular interstitial capillary fibroblasts in the renal cortex.

In CKD, progressive chronic tubulointerstitial inflammation, capillary rarefaction, and myofibroblast transdifferentiation lead to loss of functional EPO-producing cells, resulting in absolute erythropoietin deficiency.

Secondary Driver: Disordered Iron Homeostasis (Elevated Hepcidin) :

Hepcidin is an acute-phase hepatic peptide that binds and degrades ferroportin , the sole cellular iron exporter on duodenal enterocytes and reticuloendothelial macrophages.

In CKD, reduced renal clearance of hepcidin combined with chronic low-grade systemic inflammation causes chronically elevated circulating hepcidin levels.

High hepcidin blocks intestinal iron absorption and traps iron inside macrophages ( reticuloendothelial iron block ), causing severe functional iron deficiency where bone marrow erythroid precursors are starved of iron despite normal or high total body iron stores.

Uremic Toxin-Mediated Erythrocyte Survival Shortening : Uremic milieu decreases red blood cell lifespan from the normal 120 days down to 60 to 90 days, compounded by microvascular blood loss from uremic platelet dysfunction.

Diagnostic Evaluation & Iron Repletion Targets

Morphology : Classically normocytic, normochromic anemia with an inappropriately low reticulocyte count.

Laboratory Workup : Complete blood count, absolute reticulocyte count, serum ferritin, and Transferrin Saturation (TSAT) : TSAT (%) = ( Serum Iron Total Iron Binding Capacity [TIBC] ) × 100 \text{TSAT (\%)} = \left( \frac{\text{Serum Iron}}{\text{Total Iron Binding Capacity [TIBC]}} \right) \times 100 TSAT (%) = ( Total Iron Binding Capacity [TIBC] Serum Iron ) × 100

MANDATORY CLINICAL RULE: Correct Iron Deficiency Prior to Initiating ESAs :

Erythropoiesis-Stimulating Agents (ESAs) drive rapid bone marrow erythropoiesis. If iron stores are insufficient, the patient will develop functional iron deficiency, rendering the ESA completely ineffective.

KDIGO Iron Targets Prior to & During ESA Therapy :

Transferrin Saturation (TSAT) : Target > 20% (optimally 20% to 30%).

Serum Ferritin : Target > 100 ng/mL in non-dialysis CKD; Target > 200 ng/mL in maintenance hemodialysis CKD (optimally 200 to 500 ng/mL).

Route of Administration : In non-dialysis CKD, a 1- to 3-month trial of oral iron (ferrous sulfate 325 mg daily or ferric citrate) is reasonable; however, gastrointestinal intolerance and poor hepcidin-mediated absorption frequently necessitate Intravenous Iron (Iron Sucrose or Ferric Carboxymaltose) , which is universally preferred in hemodialysis patients.

Erythropoiesis-Stimulating Agents (ESAs) & The FDA Black Box Warning

Representative Agents :

Epoetin alfa (Epogen / Procrit) : Recombinant human erythropoietin; administered SC or IV 1 to 3 times weekly (half-life ~8 hours IV, ~24 hours SC).

Darbepoetin alfa (Aranesp) : Hyper-glycosylated erythropoietin analogue with 5 N-linked carbohydrate chains (compared to 3 in epoetin); extended terminal half-life (~25 hours IV, ~48 hours SC), allowing administration once weekly to once every 2 to 4 weeks. ESA CLINICAL INITIATION & TARGETING PROTOCOL

Clinical Decision Point KDIGO & FDA Guideline Recommendation
═════════════════════════════════════════════════════════════════════════════════════════════
When to INITIATE ESAs Initiate ONLY when Hemoglobin is < 10.0 g/dL
(Ensure TSAT > 20% and Ferritin > 100 ng/mL first!)

Target Hemoglobin Range Target Hemoglobin: 10.0 to 11.5 g/dL (Maintenance target ~11.0 g/dL)

FDA BLACK BOX WARNING: TARGET HEMOGLOBIN MUST NEVER EXCEED 11.5 g/dL!

Excess Cardiovascular Risk • Reduce dose by 25% if Hb increases > 1.0 g/dL in any 2-week period
Hold dose if Hb approaches or exceeds 11.5 g/dL

NEVER attempt to normalize hemoglobin (> 12.0 to 13.0 g/dL)!

═════════════════════════════════════════════════════════════════════════════════════════════

The Evidence Behind the Black Box Warning: TREAT, CHOIR & CREATE Trials :

In the landmark TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy; 4,038 diabetic CKD patients) and CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) randomized controlled trials, targeting normal hemoglobin levels (Hb 13.0 to 14.0 g/dL) using high-dose ESAs resulted in:

A twofold increase in the risk of fatal and non-fatal ischemic stroke (HR 1.92).

Significant increases in venous thromboembolism (VTE) , vascular access thrombosis (arteriovenous fistula clotting), and congestive heart failure hospitalizations.

Exacerbation of severe, uncontrolled hypertension.

Zero improvement in overall survival .

Consequently, ESAs are prescribed strictly to alleviate severe anemia symptoms and avoid allogeneic blood transfusions (which sensitize candidates to human leukocyte antigens [HLA], compromising future kidney transplant eligibility), maintaining hemoglobin strictly between 10.0 and 11.5 g/dL .